Technologies Available
Here are some of the university-developed technologies we are representing.
You can download non-confidential Technology Summary now. If you would like to learn more, we can execute a mutual confidentiality disclosure agreement.
The potential licensing terms may vary – nonexclusive, exclusive, co-exclusive, and exclusive in a particular field of use or geography. Other milestone agreements might include material transfer, sponsored research, and option to license.
Breakthrough Magnetic Bead Technology for Fast and Easy Cell Separation
TechID: MSL10_2210
TECHNOLOGY DESCRIPTION
The new superparamagnetic particles from MagSense Life Sciences, Inc, represent a breakthrough of performance in magnetic separation - the magnetic force of these particles is significantly higher and more uniform than has been previously available.
Click here to download complete Technology Summary.
Superparamagnetic particles for microfluidic biosensor
diagnostics: MagSense Beads for lab-on-a-chip
TechID: MSL10_0802
TECHNOLOGY DESCRIPTION
Early detection of infectious diseases can greatly enhance medical care and limit the spread of emerging diseases.Thus, rapid, sensitive, and inexpensive point-of-care sensors are needed to identify multiple pathogens in complex samples. Nanoparticles have unique properties that make them useful for biological and chemical sensing. We present a new development in nanoparticle synthesis for diagnostic devices: MagSense Superparamagnetic Beads.
Click here to download complete Technology Summary.
Novel, Fast-Acting “Spontaneous” Cell-Penetrating Peptides (SCPPs)
for Intracellular Drug Delivery
TechID: TUL_0603
TECHNOLOGY DESCRIPTION
The blood-brain barrier and other lipid bilayers are obstacles to penetration of hydrophilic macromolecules, including peptides used as therapeutic agents. A class of Cell-Penetrating Peptides (CPPs) has emerged as a major opportunity for improving intracellular drug delivery. We present a novel approach for overcoming low biomembrane permeability and allowing intracellular delivery of therapeutic macromolecules – the first “Spontaneous” Cell-Penetrating Peptides (or S-CPPs).
Click here to download complete Technology Summary.
TechID: TUL_0604
TECHNOLOGY DESCRIPTION
Current breast cancer management includes chemotherapy followed by endocrine therapies with selective estrogen receptor modulators (SERMs, such as tamoxifen/Nolvadex) or estrogen ablation by aromatase inhibitors (such as anastrazole/Armidex) or GnRH agonists (goserelin/Zoladex). However, resistance to chemotherapy and endocrine therapy remains a major cause of treatment failure. Evidence suggests that abnormal ceramide levels play a role, which has led to the development of a class of ceramide analogs as potential reversal agents. We present a novel approach to ceramide analogs that incorporate a new amide functional group (AFG) in the sphingosine backbone to affect antiproliferative activity in breast cancer cells. These are unique AFG-added Ceramide Analogs (AFG-CAs).
Click here to download complete Technology Summary.
TechID: TUL_0605
TECHNOLOGY DESCRIPTION
Although treatment for gynecological cancer has improved in recent years with taxane–platinum chemotherapy, the majority of patients relapse, and in most the disease remains incurable. A thorough understanding of drug resistance mechanisms is needed, as this remains the largest obstacle in treating patients with recurrent disease. Evidence suggests that abnormal ceramide levels have a role, which has led to the development of a class of ceramide analogs as potential therapies. We present a novel approach to ceramide analogs with alterations in the degree and position of unsaturation of bonds in the sphingoid backbone that affect the antiproliferative activity in cancer cells. These are unique AFG-added Ceramide Analogs (AFG-CAs).
Click here to download complete Technology Summary.
TechID: TUL_0606
TECHNOLOGY DESCRIPTION
Endocrine tumors of the thyroid, adrenal, pituitary and parathyroid glands are often overlooked in medical oncology, as many of them are effectively cured by surgery alone or with ablative radiation. For aggressive endocrine cancers that are widely metastatic or rapidly progressive, pharmacologic management becomes more important. Conventional chemotherapy has not had a significant impact. Evidence suggests that abnormal ceramide levels have a role in chemo- and hormone-therapy resistance, which has led to development of a class of ceramide analogs as potential therapies. We present a novel approach to ceramide analogs that incorporate a new amide functional group (AFG) in the sphingosine backbone to affect antiproliferative activity in endocrine cancer cells. These are unique AFG-added Ceramide Analogs (AFG-CAs).
Click here to download complete Technology Summary.
TechID: BSU10_0605
TECHNOLOGY DESCRIPTION
Nanoparticle-assisted drug delivery, cell imaging, and cancer therapy are important biomedical applications of nanotechnology. The development of core-shell nanostructures that combine multiple functions are of great interest for future uses. Some experiments with fluorescent core-shell nanoparticles to add functional cancer destroying layers have suffered from a lack of significant cell specificity. We present novel multifunction nanostructures synthesized for the first time: fluorescein isothiocyanate (FITC)-encapsulated SiO2 core-shell particles with a nanoscale ZnO finishing layer. These are the first fluorescent dye core-shell ZnO multi-functional smart nanoparticles.
Click here to download complete Technology Summary.
TechID: BSU10_0604
TECHNOLOGY DESCRIPTION
Even as knowledge of cancer at the molecular and nanometer level has improved, advances in more targeted treatments have been slow. In fact, most current cancer therapies (even newer agents) do not effectively differentiate between cancerous and normal cells. This indiscriminate action leads to systemic toxicity and adverse effects, such as bone marrow suppression, neurotoxicity, and cardiomyopathy. To target pathogenic cells while sparing healthy body tissues, we present uniquely designed Zinc Oxide Nanoparticles. ZnO-NPs apply proven synthesis, properties, and mechanisms to deliver anticancer therapy in a cell-specific manner.
Click here to download complete Technology Summary.
TechID: BSU10_0602
TECHNOLOGY DESCRIPTION
Anthracyclines are the most commonly used chemotherapy agents for cancer, including leukemia, soft tissue sarcomas, and breast and lung cancer. However, in the body, an enzyme called carbonyl reductase causes anthracycline to be converted into metabolites - which not only lowers the amount of cancer cells killed by a given does, but also contributes to cardiotoxicity and drug resistance. We present the first biphenyl compound shown to significantly inhibit carbonyl reductase: Triclosan.
Click here to download complete Technology Summary.
TechID: UID10_0801
TECHNOLOGY DESCRIPTION
Bovine leukemia virus (BLV) attacks dairy and beef cattle, transmitted through blood or colostrum. Bovine immunodeficiency virus (BIV) was initially isolated from a dairy cow with lymphocytosis, lymphadenopathy, neuropathy, and progressive emaciation. (Studies show that BIV resembles human HIV-1). Currently there is no treatment or effective vaccination against BLV or BIV. We present a patented discovery that acts selectively on BLV cells infected without harming normal cells. It also inhibits BIV replication and curtails specific aspects of BIV-induced cytopathology. Presenting non-toxic subunit A of Shiga toxin 1 for therapeutic development – the first cell-selective StxA1.
Click here to download complete Technology Summary.